Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 20/20 | 0.77 |
| ▸ | F13A1 | P00488 | 1/20 | 0.63 |
| ▸ | TGM1 | P22735 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19463544 | 1.00 | TGM2 (0.77) | TGM2F13A1TGM1 | |
| SCHEMBL15619216 | 0.97 | TGM2 (0.82) | TGM2F13A1TGM1 | |
| SCHEMBL15620427 | 0.97 | TGM2 (0.82) | TGM2F13A1TGM1 | |
| SCHEMBL15619718 | 0.97 | TGM2 (0.82) | TGM2F13A1TGM1 | |
| SCHEMBL19466024 | 0.93 | TGM2 (0.69) | TGM2F13A1TGM1 | |
| SCHEMBL19466025 | 0.93 | TGM2 (0.69) | TGM2F13A1TGM1 | |
| SCHEMBL4173691 | 0.88 | FOLH1 (0.72) | TGM2 | |
| SCHEMBL11875673 | 0.88 | FOLH1 (0.72) | TGM2 | |
| SCHEMBL4173693 | 0.88 | FOLH1 (0.72) | TGM2 | |
| SCHEMBL15619595 | 0.87 | TGM2 (1.00) | TGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442533-B1 | TG2 INHIBITOR COMPOUNDS AND USES THEREOF | UNIV OTTAWA (CA) | 2024-08-07 | — | — | EP | disclosed |
| US-10894777-B2 | TG2 inhibitor piperazine compounds and uses thereof | UNIVERSITY OF OTTAWA (CA) | 2021-01-19 | — | — | US | disclosed |
| EP-3442533-A1 | TG2 INHIBITOR COMPOUNDS AND USES THEREOF | University Of Ottawa (CA) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017179018-A1 | TG2 INHIBITOR COMPOUNDS AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894777-B2 | TG2 inhibitor piperazine compounds and uses thereof | TGM2, TGM1, TGM3 | TGM2 1/4885F13A1 1726/4885TGM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.